These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16503546)

  • 1. The effect of the JAK2 V617F mutation on PRV-1 expression.
    Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
    Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
    Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
    Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
    [No Abstract]   [Full Text] [Related]  

  • 4. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
    Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
    Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
    [No Abstract]   [Full Text] [Related]  

  • 7. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
    Mesa RA; Powell H; Lasho T; DeWald GW; McClure R; Tefferi A
    Haematologica; 2006 Mar; 91(3):415-6. PubMed ID: 16531268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
    Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; Mesa R; Li CY; Wadleigh M; Lee SJ; Gilliland DG
    Cancer; 2006 Feb; 106(3):631-5. PubMed ID: 16369984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic control of PRV-1 expression on neutrophils.
    Jelinek J; Li J; Mnjoyan Z; Issa JP; Prchal JT; Afshar-Kharghan V
    Exp Hematol; 2007 Nov; 35(11):1677-83. PubMed ID: 17976520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
    Pargade V; Darnige L; Gaussem P
    Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not just another kinase. New knowledge about myeloproliferative disease].
    Bjerrum OW
    Ugeskr Laeger; 2006 Sep; 168(39):3293. PubMed ID: 17032590
    [No Abstract]   [Full Text] [Related]  

  • 17. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.
    Goerttler PS; Steimle C; März E; Johansson PL; Andreasson B; Griesshammer M; Gisslinger H; Heimpel H; Pahl HL
    Blood; 2005 Oct; 106(8):2862-4. PubMed ID: 15985544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis.
    Percy MJ; Jones FG; Green AR; Reilly JT; McMullin MF
    Haematologica; 2006 Mar; 91(3):413-4. PubMed ID: 16503548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.